All Articles
A new disease level precision medicine model; starting with melanoma

A new disease level precision medicine model; starting with melanoma

30 May, 2017

A new model for melanoma that offers clinical and financial benefits in precision healthcare will provide substantial improvements in outcomes and costs by shifting the management of melanoma to earlier interventions when the condition is curable.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.